

CITATION REPORT

List of articles citing

Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study

DOI: 10.1186/1741-7015-7-41
BMC Medicine, 2009, 7, 41.

Source: <https://exaly.com/paper-pdf/45877882/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
112	Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)?. <i>BMC Medicine</i> , 2009 , 7, 42	11.4	10
111	Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells. 2010 , 160, 1690-8		24
110	Rapid regression of advanced hepatocellular carcinoma associated with elevation of des-gamma-carboxy prothrombin after short-term treatment with sorafenib - a report of two cases. 2010 , 3, 298-303		17
109	Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle. 2010 , 52, 771-5		68
108	An investigation of the effect of sorafenib on tumour growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal-regulated kinase levels. 2011 , 20, 1039-45		8
107	ERK1/2 deactivation enhances cytoplasmic Nur77 expression level and improves the apoptotic effect of fenretinide in human liver cancer cells. 2011 , 81, 910-6		18
106	miR-338-3p suppresses invasion of liver cancer cell by targeting smoothed. 2011 , 225, 463-72		106
105	STEROID. 2012 ,		1
104	Preferential inhibition of hepatocellular carcinoma by the flavonoid Baicalein through blocking MEK-ERK signaling. 2012 , 41, 969-78		47
103	Downregulation of FGL2/prothrombinase delays HCCLM6 xenograft tumour growth and decreases tumour angiogenesis. 2012 , 32, 1585-95		33
102	Prognostic significance and clinical relevance of Sprouty 2 protein expression in human hepatocellular carcinoma. 2012 , 11, 177-84		14
101	Enhanced erythrocyte membrane exposure of phosphatidylserine following sorafenib treatment: an in vivo and in vitro study. 2012 , 30, 876-88		67
100	Impact of restricting access to high-cost medications for hepatocellular carcinoma. 2012 , 12, 465-73		6
99	The suppressive effect of metabotropic glutamate receptor 5 (mGlu5) inhibition on hepatocarcinogenesis. 2012 , 94, 2366-75		10
98	Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC). 2012 , 14, 564-74		11
97	Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update. 2012 , 42, 523-42		38
96	Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. 2012 , 87, 277-83		20

95	Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK. 2012 , 39, 1683-9	22
94	Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma. 2013 , 33, 950-7	61
93	MEK inhibition induced downregulation of MRP1 and MRP3 expression in experimental hepatocellular carcinoma. 2013 , 13, 3	18
92	Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma. 2013 , 139, 1179-87	25
91	Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma. 2013 , 13, 363	17
90	MAT2B-GIT1 interplay activates MEK1/ERK 1 and 2 to induce growth in human liver and colon cancer. 2013 , 57, 2299-313	64
89	Sorafenib potentiates irradiation effect in hepatocellular carcinoma in vitro and in vivo. 2013 , 329, 109-17	53
88	Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib. 2013 , 39, 974-80	23
87	Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma. 2013 , 9, 153-65	15
86	A rare point mutation in the Ras oncogene in hepatocellular carcinoma. 2013 , 43, 289-92	20
85	Sorafenib delays recurrence and metastasis after liver transplantation in a rat model of hepatocellular carcinoma with high expression of phosphorylated extracellular signal-regulated kinase. 2013 , 19, 507-20	17
84	Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. 2013 , 5, 345-52	131
83	Sorafenib inhibits epithelial-mesenchymal transition through an epigenetic-based mechanism in human lung epithelial cells. 2013 , 8, e64954	26
82	Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis. 2013 , 7, 696-703	59
81	Hepatocellular carcinoma: systemic therapies and future perspectives. 2014 , 14, 1205-18	38
80	Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib. 2014 , 31, 264	36
79	Reversing multidrug resistance in hepatocellular carcinoma cells by inhibiting extracellular signal-regulated kinase/mitogen-activated protein kinase signaling pathway activity. 2014 , 8, 2333-2339	27
78	Biomarkers and Personalized Sorafenib Therapy. 2014 , 3, 399-404	14

77	Biomarkers for predicting response to tyrosine kinase inhibitors in drug-sensitive and drug-resistant human bladder cancer cells. 2015 , 33, 951-7	11
76	Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment. 2015 , 35, 2001-8	37
75	Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma. 2015 , 17, 29-37	43
74	YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models. 2014 , 4, 6031	26
73	PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment. 2015 , 5, 9384	75
72	Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma. 2015 , 11, 943-51	20
71	The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC. 2016 , 12, 3045-3050	139
70	Inhibition of acquired-resistance hepatocellular carcinoma cell growth by combining sorafenib with phosphoinositide 3-kinase and rat sarcoma inhibitor. 2016 , 206, 371-379	12
69	Endothelial progenitor cell number and ERK phosphorylation serve as predictive and prognostic biomarkers in advanced hepatocellular carcinoma patients treated with sorafenib. 2016 , 5, e1226718	9
68	Extracellular signal-regulated kinase 1 and 2 in cancer therapy: a focus on hepatocellular carcinoma. 2016 , 43, 107-16	18
67	Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells. 2016 , 14, 46	23
66	Liposome-mediated RNA interference delivery against Erk1 and Erk2 does not equally promote chemosensitivity in human hepatocellular carcinoma cell line HepG2. 2017 , 45, 1612-1619	13
65	Sorafenib inhibits 5-fluorouracil-resistant gastric cancer cell growth. 2017 , 52, 577-584	7
64	Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus. 2017 , 37, 227-234	7
63	New knowledge of the mechanisms of sorafenib resistance in liver cancer. 2017 , 38, 614-622	310
62	Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma. 2017 , 6, 2787-2795	23
61	Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma. 2017 , 12, 795-803	20
60	Peripheral blood neutrophil count as a prognostic factor for patients with hepatocellular carcinoma treated with sorafenib. 2017 , 7, 837-842	8

59	Initial analysis of peripheral lymphocytic extracellular signal related kinase activation in autism. 2017 , 84, 153-160	4
58	A 4-Phenoxyphenol Derivative Exerts Inhibitory Effects on Human Hepatocellular Carcinoma Cells through Regulating Autophagy and Apoptosis Accompanied by Downregulating β Tubulin Expression. 2017 , 22,	14
57	Molecular signatures in hepatocellular carcinoma: A step toward rationally designed cancer therapy. 2018 , 124, 3084-3104	35
56	Capsaicin enhances the antitumor activity of sorafenib in hepatocellular carcinoma cells and mouse xenograft tumors through increased ERK signaling. 2018 , 39, 438-448	28
55	Antrodia cinnamomea boosts the anti-tumor activity of sorafenib in xenograft models of human hepatocellular carcinoma. 2018 , 8, 12914	10
54	Pyran-2-one derivatives from <i>Croton crassifolius</i> as potent apoptosis inducers in HepG2 cells via p53-mediated Ras/Raf/ERK pathway. 2018 , 79, 355-362	7
53	Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines. 2018 , 144, 1487-1501	17
52	Autophagic cell death associated to Sorafenib in renal cell carcinoma is mediated through Akt inhibition in an ERK1/2 independent fashion. 2018 , 13, e0200878	19
51	Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer. 2018 , 69, 1057-1065	46
50	Proteomic Profile of Sorafenib Resistance in Hepatocellular Carcinoma; GRP78 Expression Is Associated With Inferior Response to Sorafenib. 2019 , 16, 569-576	10
49	Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology. 2019 , 18, 1506-1519	9
48	Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib. 2019 , 31, 1250-1255	12
47	Yin Yang Gong Ji pill is an ancient formula with antitumor activity against hepatoma cells. 2020 , 248, 112267	4
46	Activation of extracellular signal-regulated kinase is associated with hepatocellular carcinoma with aggressive phenotypes. 2020 , 50, 353-364	5
45	A Phase I Trial of Trametinib in Combination with Sorafenib in Patients with Advanced Hepatocellular Cancer. 2020 , 25, e1893-e1899	6
44	Triggered ROS-Induced DNA Damage to Arrest Cell Cycle Progression and Induce Apoptosis on Human Hepatocellular Carcinoma In Vitro and In Vivo. 2020 , 25,	2
43	Krill oil extract inhibits the migration of human colorectal cancer cells and down-regulates EGFR signalling and PD-L1 expression. 2020 , 20, 372	4
42	Liver Fibrosis and Inflammation under the Control of ERK2. 2020 , 21,	7

41	Comprehensive network analysis of the molecular mechanisms associated with sorafenib resistance in hepatocellular carcinoma. 2020 , 245, 27-34		4
40	Emerging importance of molecular pathogenesis of vascular malformations in clinical practice and classifications. 2020 , 25, 364-377		10
39	Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity. <i>Cancers</i> , 2020 , 12,	6.6	41
38	A novel prognostic index of hepatocellular carcinoma based on immunogenomic landscape analysis. 2021 , 236, 2572-2591		11
37	Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint. 2016 , 7, 41274-41284		28
36	Transcriptomic characterization reveals prognostic molecular signatures of sorafenib resistance in hepatocellular carcinoma. 2021 , 13, 3969-3993		3
35	Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma. 2022 , 42, 112-155		9
34	Dihydroartemisinin as a Sensitizing Agent in Cancer Therapies. 2021 , 14, 2563-2573		5
33	Fibrinogen-Like Protein 1 Modulates Sorafenib Resistance in Human Hepatocellular Carcinoma Cells. 2021 , 22,		4
32	The human vault RNA enhances tumorigenesis and chemoresistance through the lysosome in hepatocellular carcinoma. 2021 , 1-13		3
31	RAF-MEK-ERK pathway in cancer evolution and treatment. 2021 ,		7
30	Targeting Na ⁺ /K ⁺ -ATPase by berbamine and ouabain synergizes with sorafenib to inhibit hepatocellular carcinoma. 2021 , 178, 4389-4407		2
29	miR-126-3p contributes to sorafenib resistance in hepatocellular carcinoma via downregulating SPRED1. 2021 , 9, 38		3
28	A multi-omics approach expands the mutational spectrum of MAP2K1-related melorheostosis. 2020 , 137, 115406		1
27	BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib. 2013 , 8, e83627		53
26	The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value. 2015 , 6, 26388-99		8
25	pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma. 2016 , 7, 2646-59		35
24	MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines. 2017 , 37, 2831-2838		10

23	Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells. 2020 , 22,		8
22	Biomarkers for hepatocellular carcinoma: What's new on the horizon?. 2018 , 24, 3974-3979		26
21	Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out. 2014 , 6, 830-5		14
20	Stem Cell-based Therapy Strategy for Hepatic Fibrosis by Targeting Intrahepatic Cells. 2021 , 1		1
19	Proposed treatment guidance on new anticancer agents for the treatment of hepatocellular carcinoma, 2010 up date. 2011 , 52, 532-551		
18	Biomarqueurs prédictifs d'efficacité 2013 , 289-304		
17	Efficacy and optimal treatment sequence of Sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. 2013 , 54, 233-248		1
16	Better Management of Adverse Events Favors Sorafenib Treatment of HCC Patients and Impact on Survival. 2016 , 07, 275-284		1
15	Phospho-ERK is a response biomarker to a combination of sorafenib and MEK inhibition in liver cancer.		
14	The MEK inhibitors enhance the efficacy of sorafenib against hepatocellular carcinoma cells through reducing p-ERK rebound.. 2019 , 8, 1224-1232		0
13	Identification and validation of potential key long noncoding RNAs in sorafenib-resistant hepatocellular carcinoma cells. 2020 , 8, e8624		1
12	ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma. <i>Neoplasia</i> , 2021 , 23, 1227-1239	6.4	5
11	A multidisciplinary approach to the management of hepatocellular carcinoma. <i>Gastroenterology and Hepatology</i> , 2010 , 6, 1-16	0.7	7
10	Molecular signaling and its role in drug resistance in hepatocellular carcinomas. 2022 , 209-225		
9	Dysregulated cell-signaling pathways in hepatocellular carcinoma: causes and therapeutic options. 2022 , 337-355		
8	Rescuing SLAMF3 Expression Restores Sorafenib Response in Hepatocellular Carcinoma Cells through the Induction of Mesenchymal-to-Epithelial Transition.. <i>Cancers</i> , 2022 , 14,	6.6	1
7	Aloperine: A Potent Modulator of Crucial Biological Mechanisms in Multiple Diseases.. <i>Biomedicines</i> , 2022 , 10,	4.8	1
6	A phase I clinical trial of trametinib in combination with TAS-102 in patients with chemotherapy-resistant RAS-mutated (PIK3CA/PTEN-wild type) metastatic colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2022 ,	3.8	

- 5 Improving the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma by Repurposing Disulfiram. *Frontiers in Oncology*, 12, 53 ○
- 4 Ferroptosis-Related Hub Genes in Hepatocellular Carcinoma: Prognostic Signature, Immune-Related, and Drug Resistance Analysis. 13, ○
- 3 Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma. **2022**, 8, ○
- 2 miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma. **2022**, 11, 2673 ○
- 1 Loss-of-SIRT7 sensitizes hepatocellular carcinoma to sorafenib through the regulation of ERK Phosphorylation. ○